• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Covid-19: Monoclonal antibodies authorised in US as alternative to vaccines for certain groups.

作者信息

Kmietowicz Zosia

机构信息

The BMJ.

出版信息

BMJ. 2021 Dec 10;375:n3064. doi: 10.1136/bmj.n3064.

DOI:10.1136/bmj.n3064
PMID:34893506
Abstract
摘要

相似文献

1
Covid-19: Monoclonal antibodies authorised in US as alternative to vaccines for certain groups.新冠病毒：单克隆抗体在美国获批，可供特定群体作为疫苗的替代选择。
BMJ. 2021 Dec 10;375:n3064. doi: 10.1136/bmj.n3064.
2
Monoclonal Antibodies vs COVID-19: Eduardo Ojito-Magaz MS General Director, Molecular Immunology Center.单克隆抗体与 COVID-19：Eduardo Ojito-Magaz 医学博士，分子免疫学中心主任。
MEDICC Rev. 2021 Apr;23(2):12. doi: 10.37757/MR2021.V23.N2.17. Epub 2021 Apr 30.
3
Vaccine or monoclonal therapy: which is the winning weapon against COVID-19?疫苗还是单克隆疗法：哪一种是对抗新冠病毒的制胜武器？
J Glob Antimicrob Resist. 2021 Sep;26:202-204. doi: 10.1016/j.jgar.2021.05.021. Epub 2021 Jul 7.
4
Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases.人源单克隆抗体对 SARS-CoV-2 蛋白与组织抗原的反应：对自身免疫性疾病的影响。
Front Immunol. 2021 Jan 19;11:617089. doi: 10.3389/fimmu.2020.617089. eCollection 2020.
5
COVID-19 global pandemic: vaccines and new monoclonal antibodies, aspects to be clarified.新型冠状病毒肺炎全球大流行：疫苗与新型单克隆抗体，有待阐明的方面。
Immunol Res. 2021 Apr;69(2):115-116. doi: 10.1007/s12026-021-09193-5. Epub 2021 Apr 15.
6
Pigs Don't Fly and You Cannot Expect Absolutely Safe COVID-19 Vaccines (But You Should Expect a Fair Compensation).猪不会飞，你也不能指望 COVID-19 疫苗绝对安全（但你应该期望得到公平的赔偿）。
Eur J Health Law. 2021 Apr 19;28(2):165-183. doi: 10.1163/15718093-BJA10042.
7
Considerations for fair prioritization of COVID-19 vaccine and its mandate among healthcare personnel.医疗保健人员 COVID-19 疫苗公平优先排序及其授权的考虑因素。
Curr Med Res Opin. 2021 Jun;37(6):907-909. doi: 10.1080/03007995.2021.1908245. Epub 2021 Apr 9.
8
Are mimotope vaccines a good alternative to monoclonal antibodies?拟态疫苗是否是单克隆抗体的良好替代品？
Immunotherapy. 2019 Jun;11(9):795-800. doi: 10.2217/imt-2018-0213. Epub 2019 May 16.
9
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
10
Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union.欧盟集中授权药品的用药错误风险管理描述。
Drug Saf. 2020 Jan;43(1):45-55. doi: 10.1007/s40264-019-00874-7.

引用本文的文献

1
Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period.AZD7442（替沙格韦单抗/西加韦单抗）在以色列奥密克戎亚变体时期用于预防COVID-19住院的暴露前预防效果。
Infect Dis Ther. 2025 Feb;14(2):433-445. doi: 10.1007/s40121-024-01100-3. Epub 2025 Jan 7.
2
Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups.在以色列最大的健康维护组织中实施AZD7442（替沙格韦单抗/西加韦单抗）预防新型冠状病毒肺炎暴露前预防（PrEP）：免疫功能低下患者群体的真实世界接受情况以及社会人口学和临床特征
Infect Dis Ther. 2024 Jun;13(6):1379-1389. doi: 10.1007/s40121-024-00981-8. Epub 2024 May 10.
3
The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.替沙格韦单抗/西加韦单抗（Evusheld）在免疫功能低下患者 COVID-19 预防和治疗中的疗效：系统评价和荟萃分析。
Eur J Med Res. 2024 Jan 5;29(1):27. doi: 10.1186/s40001-023-01549-x.
4
Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand.埃夫塞米用于高危人群 COVID-19 暴露前预防的经济评价：来自泰国的早期证据。
Appl Health Econ Health Policy. 2023 May;21(3):511-522. doi: 10.1007/s40258-023-00796-7. Epub 2023 Mar 16.
5
Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies.用单克隆抗体中和 SARS-CoV-2 和其他人类冠状病毒的广泛策略。
Sci China Life Sci. 2023 Apr;66(4):658-678. doi: 10.1007/s11427-022-2215-6. Epub 2022 Nov 24.
6
Tixagevimab and Cilgavimab: Can we see More Recommendations for Monoclonal Antibodies Beyond COVID-19 Vaccination.替沙格韦单抗和西加韦单抗：除了新冠疫苗接种之外，我们能否看到更多关于单克隆抗体的建议？
Disaster Med Public Health Prep. 2022 Jun 8:1-2. doi: 10.1017/dmp.2022.150.
7
and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2.及其成分金丝桃素和假金丝桃素对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）具有抗病毒活性。
Pharmaceuticals (Basel). 2022 Apr 25;15(5):530. doi: 10.3390/ph15050530.
8
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).2021 年欧洲白血病感染会议（ECIL 9）关于血液系统恶性肿瘤或造血细胞移植患者 COVID-19 管理的建议。
Leukemia. 2022 Jun;36(6):1467-1480. doi: 10.1038/s41375-022-01578-1. Epub 2022 Apr 29.